PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Semaglutide

Drugs in development · updated 30 October 2026

Semaglutide: clinical trials and development status

Other names and codes: Wegovy, Rybelsus, Ozempic, Wegovy Flextouch, Kayshild

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 8 February 2018

As of 30 October 2026 Semaglutide is in 147 active clinical trials (recruiting or ongoing, phases I–III) for 72 diseases. The most advanced phase is III.

147Active trials
IIIMost advanced phase
72Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Semaglutide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 72 diseases.

DiseaseMost advanced phaseActive trialsReference trial
ObesityIII60NCT07845500
Type 2 diabetesIII30NCT07662213
OverweightIII24NCT07845500
Type-1 diabetesIII12NCT05819138
Insulin resistanceIII6NCT07770282
AlcoholismIII5NCT07218354
Non-alcoholic Fatty Liver DiseaseIII5NCT04822181
Weight lossIII5NCT06909006
Cardiovascular diseaseIII4NCT05669755
Ischemic strokeIII4NCT07030621
Metabolic syndromeIII4NCT07770282
Chronic renal insufficiencyIII3NCT06058585
DiabetesII–III3NCT06387199
Pediatric ObesityIII3NCT06934655
Gestational diabetesIII2NCT05569772
Heart failureIII2NCT07090343
Human body weightIII2NCT07866066
Myocardial infarction with ST segment elevationIII2NCT07295223
Aortic valve stenosisIII1NCT07090343
Atrial fibrillationIII1NCT06499857
Body weight changeIII1NCT07294950
CraniopharyngiomaIII1NCT07845994
Diabetic footIII1NCT07581145
Endocrine system diseaseIII1NCT06260722
Feeding behaviorIII1NCT07021937
Glucose metabolism diseaseIII1NCT06260722
InfertilityIII1NCT05586802
Klinefelter's syndromeIII1NCT05586802
Metabolic diseaseIII1NCT06260722
Nutrition disorderIII1NCT07845500

Everything on Semaglutide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch